Publications by authors named "Tamas Pregun"
Purpose: The purpose of this study was to report 3 cases of a single-piece, acrylic, foldable, modified C loop posterior chamber intraocular lens (PCIOL) dislocated into the vitreous cavity after Descemet stripping automated endothelial keratoplasty (DSAEK).
Method: We describe the clinical course and management of the 3 cases in which a previously implanted foldable, single-piece, acrylic posterior chamber intraocular lens with modified C loops dislocated into the vitreous in association with DSAEK. Surgical management consisted of pars plana vitrectomy in each case with either PCIOL repositioning (2 cases) or PCIOL exchange (1 case) and with different fixation methods, combined with repeated DSAEK in 1 case with previous primary graft failure.
Article Synopsis
- This study aimed to evaluate the long-term efficacy, safety, immunogenicity, and pharmacokinetics of the ranibizumab biosimilar SB11 compared to the original ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD).
- Conducted as a multicenter, randomized, double-masked, parallel-group phase III equivalence trial with 705 participants, the study involved monthly intravitreal injections of either SB11 or RBZ and followed participants for 52 weeks.
- Results showed comparable visual outcomes, safety profiles, and immune responses between SB11 and RBZ, confirming that SB11 is a suitable alternative to RBZ in treating nAMD.
Article Synopsis
- Neovascular age-related macular degeneration is a major cause of blindness in people over 50, and the ranibizumab biosimilar (SB11) could provide a more accessible treatment option.
- A phase 3 study involving 705 participants was conducted across 75 centers in multiple countries to compare the efficacy, safety, and immunogenicity of SB11 to the reference drug ranibizumab.
- Results showed that the visual acuity and central subfield thickness improvements were similar between the two treatments, indicating that SB11 is a viable alternative to ranibizumab.